Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

MP Pistillo, V Fontana, A Morabito, B Dozin… - Cancer Immunology …, 2019 - Springer
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and
improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We …
被引用次数：77 相关文章

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.

MP Pistillo, V Fontana, A Morabito, B Dozin… - Cancer Immunology …, 2018 - europepmc.org
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and
improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We …

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

MP Pistillo, V Fontana, A Morabito… - Cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and
improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We …

[引用][C] Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

MP Pistillo, V Fontana, A Morabito, B Dozin… - Cancer Immunology …, 2018 - cir.nii.ac.jp
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated
with ipilimumab: an Italian melanoma intergroup study | CiNii Research CiNii 国立情報学研究所 …

[引用][C] Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

MP Pistillo, V Fontana, A Morabito, B Dozin… - CANCER …, 2019 - iris.unito.it

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.

MP Pistillo, V Fontana, A Morabito… - Cancer Immunology …, 2019 - search.ebscohost.com
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and
improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We …

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

MP Pistillo, V Fontana, A Morabito… - Cancer Immunology …, 2019 - search.proquest.com
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and
improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We …